In addition to this, PAK1 induces a stemness phenotype in NSCLC cells by increasing β-Catenin expression via ERK/GSK3β, thereby resulting in the resistance of NSCLC cells to cisplatin [184]. This evidence concerns the gene GSK3B and non-small cell lung carcinoma.